Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Gimatecan in Advanced Ovarian Epithelial Cancer
Previous Study | Return to List | Next Study

A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04029909
Recruitment Status : Recruiting
First Posted : July 23, 2019
Last Update Posted : July 23, 2019
Sponsor:
Information provided by (Responsible Party):
Lee's Pharmaceutical Limited

Brief Summary:
This is a Phase 1, open-label, dose-escalation ,and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. To explore the dose-limiting toxicity (DLT) and the maximum tolerable dose (MTD) of oral administration of Gimatecan capsules 5 consecutive days, every 28 days.

Condition or disease Intervention/treatment Phase
Ovarian Epithelial Cancer Fallopian Tube Cancer Primary Peritoneal Cancer Drug: Gimatecan 0.6mg/m2/d Drug: 0.8mg/m2/d Drug: 0.4mg/m2/d Phase 1

Detailed Description:
The clinical trial is used the traditional 3 +3 design and conducted in two dose groups, 0.6mg/m2/d and 0.8mg/m2/d, with an improved dose escalation design. The initial dose is 0.6mg/m2, once a day for 5 consecutive days, every 28 days for a course of treatment. Subjects are assigned to the corresponding dose group according to the order of enrolling. DLT is observed within 28 days of the first dose of Gimatecan. In the absence of DLT as prescribed by the protocol, the next dose group is started until the maximum tolerated dose (MTD) is observed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Clinical Study of Gimatecan (ST 1481) in Patients With Platinum-resistant or Sensitive Relapsing/Refractory Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Actual Study Start Date : July 11, 2019
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2022


Arm Intervention/treatment
Experimental: Gimatecan 0.6mg/m2/d
Three or six patients will be treated with the dose of 0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
Drug: Gimatecan 0.6mg/m2/d
0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan

Experimental: Gimatecan 0.8mg/m2/d
Three or six patients will be treated with the dose of 0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
Drug: 0.8mg/m2/d
0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan

Experimental: Gimatecan 0.4mg/m2/d
Three or six patients will be treated with the dose of 0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
Drug: 0.4mg/m2/d
0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan




Primary Outcome Measures :
  1. Dose limiting toxicity(DLT) [ Time Frame: 28 days after first dose ]
    Adverse events of level 3 or above related to the study drug occurring within 28 days after the first dose as assessed by CTCAE v5.0.


Secondary Outcome Measures :
  1. Maximal tolerable dose(MTD) [ Time Frame: 28 days after first dose ]
    DLT occurs in less than 1/6 subjects, this lower dose is defined as MTD.


Other Outcome Measures:
  1. The overall response rate(ORR) [ Time Frame: through study completion, an average of 2 years ]
    The proportion of subjects who achieve the optimal objective response rate(PR or CR).

  2. AUC(0-t) [ Time Frame: 28 days after first dose ]
    Area under curve 0-t

  3. Cmax [ Time Frame: 28 days after first dose ]
    Peak concentration

  4. Tmax [ Time Frame: 28 days after first dose ]
    Peak concentration

  5. T1/2 [ Time Frame: 28 days after first dose ]
    Half life



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have stage III or IV ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer.
  2. Definite histopathological diagnosis.
  3. Failed with treatment for taxane/doxorubicin and platinum.
  4. Must have measurable disease with at least 1 unidimensional measurable lesion base on RECIST1.1. When evaluating the efficacy of patients with CA125 level, CA125 abnormalities caused by other reasons should be excluded. According to the Gynecologic Cancer Intergroup-GCIG standard, the baseline serum CA125 level of patients within 2 weeks before treatment should be ≥2 upper limit of normal.
  5. Age between 18-65(inclusive).
  6. ECOG(Eastern Cooperative Oncology Group) performance status of 0 or 1.
  7. To estimated life expectancy of at least 3 months.
  8. Appropriate blood routine, liver and kidney function.
  9. No allergic history of camptothecin.
  10. Patients who are able to take strict contraceptive measures during the trial and within 4 months after the end of the trial.
  11. The patients are able to swallow and maintain oral medication.
  12. More than 4 weeks from the end of previous surgery, chemotherapy, radiotherapy (non-pelvic and peritoneal sites) and targeted therapy before the study and the body had recovered (the treatment-related toxicity grade is no more than grade 1, except for hair loss and pigmentation).
  13. Patients voluntarily give written informed consent to participate in the study.

Exclusion Criteria:

  1. The patients are treated with irinotecan or topotecan or with any topoisomerase I inhibitor regimen prior to enrollment.
  2. Patients who use other experimental drugs or conducted other clinical trials at the same time within 30 days before participate in the study.
  3. To received radiotherapy of pelvic cavity and abdomen.
  4. Smoking more than 5 cigarettes per day in the past year.
  5. Suspected or real alcohol dependence with an average alcohol intake of more than 2 units per day for 3 months.
  6. Active infection.
  7. patients with the history of gastrointestinal surgery or that may change drug absorption and activity in the body.
  8. Serious cardiovascular disease, including Ⅱ magnitude abnormal cardiac function.
  9. having a clear history of neuropathy or mental disorders (including epilepsy or dementia).
  10. Human immunodeficiency virus(HIV) positive, untreated active hepatitis.
  11. Suffering from other malignant tumors other than this diseases in 5 years, except for basal cell carcinoma of skin, skin squamous cell carcinoma, primary cervical carcinoma and breast cancer without recurrence and metastasis after radical operation.
  12. Brain metastasis.
  13. Female with pregnant or lactating.
  14. Patients who are considered unsuitable to participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04029909


Contacts
Layout table for location contacts
Contact: Hong Zheng, MD 13641356816 Zhhong306@Hotmail.com

Locations
Layout table for location information
China, Beijing
Beijing Tumor Hospital Recruiting
Beijing, Beijing, China
Contact: Hong Zheng, MD    13641356816    Zhhong306@Hotmail.com   
Sponsors and Collaborators
Lee's Pharmaceutical Limited
Investigators
Layout table for investigator information
Study Director: Hong Zheng, MD Beijing Tumor Hospital
Layout table for additonal information
Responsible Party: Lee's Pharmaceutical Limited
ClinicalTrials.gov Identifier: NCT04029909    
Other Study ID Numbers: NTL-LEES-2018-01
First Posted: July 23, 2019    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Fallopian Tube Neoplasms
Carcinoma, Ovarian Epithelial
Peritoneal Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Ovarian Neoplasms
Endocrine Gland Neoplasms
Ovarian Diseases
Abdominal Neoplasms
Digestive System Neoplasms
Fallopian Tube Diseases
Adnexal Diseases
Carcinoma
Endocrine System Diseases
Gonadal Disorders
Digestive System Diseases
Peritoneal Diseases